<DOC>
	<DOCNO>NCT02597387</DOCNO>
	<brief_summary>To study efficacy safety Mitoxantrone HCL Liposome Injection patient diffuse large B-cell lymphoma lymphoma peripheral T cell .</brief_summary>
	<brief_title>Clinical Trial Mitoxantrone HCL Liposome Injection Patients With Relapsed DLBCL PT/NKCLs</brief_title>
	<detailed_description>A Single-arm , Open , Multi-center Phase II Clinical Trial Mitoxantrone HCL Liposome Injection Subjects With Relapsed Diffuse Large B-cell Lymphoma Peripheral T/NK Lymphomas dose 20 mg/m2 .</detailed_description>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>The subject voluntary sign inform consent form ; ECOG score 0 2 ; The expect survival time ≥3 month ; Diffuse large Bcell peripheral T/NK cell nonHodgkin 's lymphoma confirm histopathology , peripheral T/NK cell lymphomas limit follow type : peripheral Tcell lymphoma ( otherwise specify ) , angioimmunobl ; Failure relapse least systemic treatment , patient receive autologous peripheral blood stem cell transplantation The major diameter single measurable lesion ≥1.5 cm least one measurable lesion ; An interval least four week target tumor treat chemotherapy , radiotherapy , biological therapy , stem cell transplantation study drug ; Subjects childbearing age agree take effective contraceptive measure study ; blood pregnancy test result negative ( except infertility due menopause operation ) ; Laboratory test ( blood routine , liver kidney function ) meet following requirement : ANC≥ 1.5×109/L , bone marrow involvement , ANC ≥ 1.0×109/L ; PLT ≥ 75×109/L , bone marrow involvement , PLT ≥ 50 × 109/L ; Hb ≥ 9 g/dL ; ) Cr ) ≤ 1.5x ULN ; TBIL ≤ 1.5x ULN ; AST ALT ≤2.5 x ULN ( patient liver metastasis , ≤ 5 x ULN ) . Pregnant lactating woman ; An allergic history anthracyclines liposome drug ; Disease progression recurrence anthracycline treatment within six month enrollment ; '' Patients use mitoxantrone injection ; Patients use doxorubicin ( pirarubicin ) total cumulative dose &gt; 360mg/m2 , epirubicin total cumulative dose &gt; 600mg/m2 ; Left ventricular ejection fraction &lt; 50 % &lt; low limit normal ; clinically significant QT interval prolongation ( &gt; 450ms male , &gt; 470ms female ) ; past history cardiac disease cause anthracyclines ; history severe heart disease ; Concomitant treatment anticancer drug need ; Lymphoma involve central nervous system ; Clinically active infection significantly affect clinical trial ; Within 6 week organ transplantation major organ surgery ; Those inappropriate enrol evaluated researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>